# Shukui Qin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shukui-qin-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,967 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 42 |
| i10-index | 73 |
| Last Known Institution | China Pharmaceutical University |
| OpenAlex ID | https://openalex.org/A5081604639 |
| ORCID iD | https://orcid.org/0000-0002-3414-2790 |
| Works | 186 |

## Researcher papers

- [Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-treatment-of-hepatocellular-carcinoma-2019/)
- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification](https://scholariq.org/papers/phase-ii-open-label-single-arm-trial-of-imatinib-mesylate-in-patients-with/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial](https://scholariq.org/papers/icotinib-versus-gefitinib-in-previously-treated-advanced-non-small-cell-lung/)
- [Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/durvalumab-with-or-without-bevacizumab-with-transarterial-chemoembolisation-in/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)
- [Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial](https://scholariq.org/papers/afatinib-beyond-progression-in-patients-with-non-small-cell-lung-cancer/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Researcher university

- [China Pharmaceutical University](https://scholariq.org/institutions/china-pharmaceutical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.